Jens Herold

Dr. Herold is a specialist of the coronavirus since 1990. He is Head of Global Biopharmaceutical Project Management and Global TechRA at the Biopharmaceutical Business Unit of Boehringer Ingelheim, Germany, a world leader in contract manufacturing of biopharmaceuticals, since 2012. He has held senior management positions in biopharmaceutical companies during the last 20 years, and has extensive entrepreneurial experience.

From 2006 to 2012 Dr. Herold was Head of Project Management at Trion Pharma, Munich, Germany, a biotech company developing tri-functional, bispecific antibodies, and responsible for the development and successful registration of catumaxomab in Europe. Previously Dr. Herold was Project Manager at Vakzine Projekt Management, Hannover, Germany, a vaccine development company where he was responsible for the development of a cytomegalovirus vaccine candidate.

Dr. Herold was the co-founder of two biotechnology companies, Allagon Pharma in Munich, Germany in 2005 and Iguazu Biosciences in San Francisco, California, a company with focus on prophylactic vaccines against HIV and SARS, he also co-founded with Mr. Brandys in 2001.

Dr. Herold started research on the coronavirus in 1990 and concluded his Ph.D. thesis on coronavirus in the laboratory of Prof. S.G. Siddell at the University of Würzburg, Germany in 1995. Dr. Herold received the prize of the Leopoldina Academy of Natural Sciences in 1998 for scientific research abroad.